Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy

Abstract

In this largest metastatic CRC series published to date, Y90 radioembolization was found to be safe; survival varied by prior therapy. Further studies are required to further refine the role of Y90 in metastatic CRC.

Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival

“…Based on these results, patients with both borderline high bilirubin and borderline high tumor volume levels should not be excluded from 90 Y radioembolization, which is in line with the results of Jacobs et al [6]. However, other studies suggest a higher risk of early mortality in patients with a higher tumor burden [22][23][24][25].…”

Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy

“…The median OS was five months in this group, and significantly less compared to a median of eight months in patients with tumour burden below 50 % (p = 0.018), similar to previous findings [29][30][31]. Median OS was also significantly prolonged in patients with an ECOG performance scale <1 (p = 0.012), which is a subjective, but well-established clinical marker for survival stratification after SIRT [30][31][32]. However, it did not reach statistical significance on multivariate analysis.…”

Yttrium-90 Radioembolization is a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases: Further Evidence in Support of a New Treatment Paradigm

“…They remind us that patients with chemorefractory colorectal liver metastases have a median survival of only 4-6 months with best supportive care. 1 In the setting of such chemorefractory disease, Saxena et al report a median overall survival of 10.5 months from first Y90 radioembolization, which is nearly identical to the 10.6-month median survival most recently reported by Lewandowski et al in a study of 214 patients treated with glass Y90 microspheres over 12 years, 2 and a median survival of 10.5 months reported by Kennedy et al among responders in a multi-institutional review of 208 patients treated with resin Y90 microspheres. 3 The study confirms that Y90 radioembolization is safe in patients who have received multiple lines of chemotherapy, with the vast majority of clinical toxicities being low-grade and self-limited.…”